Medivation Inc (MDVN)

MDVN (NASDAQ:Drugs)
$75.90
neg -0.31
-0.41%
Today's Range: 75.36 - 77.28 | MDVN Avg Daily Volume: 947,100
Last Update: 07/30/14 - 12:50 PM EDT
Volume: 236,622
YTD Performance: 19.41%
Open: $76.99
Previous Close: $76.21
52 Week Range: $48.15 - $88.20
Oustanding Shares: 76,523,977
Market Cap: 5,839,544,685
6-Month Chart
TheStreet Ratings Grade for MDVN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 10 10 10 9
Moderate Buy 0 0 0 0
Hold 4 4 4 5
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 1.80 1.80 1.80 1.93
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -195.67
Price Earnings Comparisons:
MDVN Sector Avg. S&P 500
-195.67 0.00 28.94
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
27.02% 34.15% 618.28%
GROWTH 12 Mo 3 Yr CAGR
Revenue 50.20 3.37 0.63
Net Income 0.00 0.25 0.00
EPS 0.00 0.14 0.00
Earnings for MDVN:
EBITDA -0.02B
Revenue 0.27B
Average Earnings Estimates
Qtr (06/14) Qtr (09/14) FY (12/14) FY (12/15)
Average Estimate $0.25 $0.48 $1.37 $2.93
Number of Analysts 7 7 8 8
High Estimate $0.34 $0.95 $1.68 $4.57
Low Estimate $0.20 $-0.07 $1.11 $1.73
Prior Year $-0.07 $-0.18 $-0.57 $1.37
Growth Rate (Year over Year) 463.27% 368.25% 339.47% 114.38%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

bearishMedivation price target, EPS cut at UBS

Mar 3, 2014 | 7:49 AM EST

MDVN lowered its numbers, UBS said. Driven by disappointing Xtandi guidance. $85 price target and Buy rating, 

bearishMedivation downgraded at Needham

Feb 3, 2014 | 7:36 AM EST

MDVN was downgraded from Buy to Hold, Needham said. Valuation call. 

 

bullishMedivation price target, EPS lifted at UBS

Jan 29, 2014 | 7:31 AM EST

MDVN raised its price target and estimates through 2015, UBS said. Better-than-expected full PREVAIL data, appearing favorably vs Zytiga on a cross-trial comparison basis. $93 price target and Buy rating. 

bullishMedivation upgraded at UBS

Jul 17, 2013 | 7:57 AM EDT

MDVN was upgraded to Buy from Neutral and given a $74 price target, said UBS. The upgrade comes ahead of the ph3 PREVAIL study.

bullishMedivation rated new Buy at Needham

Mar 4, 2013 | 7:09 AM EST

MDVN was initiated with a Buy rating, Needham said. Xtandi is rapidly gaiing market share for the treatment of prostate cancer.

 

updateMedivation rated new Neutral at UBS

Dec 19, 2012 | 8:44 AM EST

MDVN was initiated with a Neutral rating, UBS said. $59 price target. Xtandi should drive conversion to profitability, but peak expectations high. 

bullishMedivation numbers raised at Jefferies

Nov 12, 2012 | 8:09 AM EST

Shares of MDVN now seen reaching $62, Jefferies said. Estimates also raised on Xtandi beat. Buy rating.

By

Adam Feuerstein and Gregg Greenberg

 | Oct 26, 2012 | 5:00 AM EDT

Adam Feuerstein, Sr. Columnist for TheStreet, says biotech earnings are the next big things to watch in biotech.

bullishMedivation numbers raised at Citigroup

Oct 3, 2012 | 7:35 AM EDT

Shares of MDVN now seen reaching $70, Citigroup said. Estimates also increased to reflect higher Xtandi US price. Buy rating.

By

Jim Cramer

 | Sep 4, 2012 | 10:48 AM EDT

Motivated CEOs, innovative products and smart deals count more than macro events.

The market has given its Q2 GDP driven gains earlier in day and is now down with the excep...
Gary D/Paul P: The drives lower in various Eurozone sovereign yields reflect the somewhat-...
If you or I printed up perfect euros, yen or dollars and circulated them... we would be pu...
Shockingly there was no increase in new lows on that whoosh down. Fear and Greed is now at...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.